This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire

MILAN, Sept. 05, 2025 (GLOBE NEWSWIRE) — AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated clinical data from the LUCE-1 study at the 25th European Society of Retina Specialists (EURETINA) Annual Congress (EURetina 2025) , taking place in Paris 4-7 September 2025.

Data presented by Prof. Simonelli included safety data for the first 11 participants treated (the 5 participants from the low dose cohort, 5 participants from the medium dose cohort

See Full Page